Ranolazine
ASPRUZYO SPRINKLE
Anti-anginal
NADAC/unit
$0.1655
No Shortage
Tier 1: 38.9%
20 Manufacturers
40 ANDAs
Ranolazine extended-release tablet is indicated for the treatment of chronic angina.
vs. brand ASPRUZYO SPRINKLE: Generic saves up to 98% per unit
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2023-11-15 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
ACTAVIS ELIZABETH LLCAJANTA PHARMA LTDALKEM LABORATORIES LTDARTHUR GROUP LLCAUROBINDO PHARMA LTDCADILA HEALTHCARE LTDCHARTWELL RX SCIENCES LLCGLENMARK PHARMACEUTICALS LTDHETERO LABS LTD UNIT IIII3 PHARMACEUTICALS LLCJUBILANT GENERICS LTDMANKIND PHARMA LTDMICRO LABS LTDNOVAST LABORATORIES LTDPIRAMAL HEALTHCARE UK LTDRISING PHARMA HOLDINGS INCSCIEGEN PHARMACEUTICALS INCSUNSHINE LAKE PHARMA CO LTDUNICHEM LABORATORIES LTDVKT PHARMA PRIVATE LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.